PLC Medical Systems Names Lead Investigators for Pivotal Trial to Evaluate RenalGuard System(TM) and RenalGuard Therapy(TM)

Trial designed to evaluate effectiveness of RenalGuard(TM) in preventing Contrast -Induced Nephropathy
FRANKLIN, Mass., Dec. 19 /PRNewswire-FirstCall/ -- PLC Systems Inc. , a company focused on innovative cardiac and vascular medical device-based technologies, announced today that it has named two lead investigators for the upcoming pivotal trial of its RenalGuard Therapy(TM). The lead investigators are Charles Davidson, MD, Professor of Medicine, Northwestern University Medical School and Richard J. Solomon, MD, Professor of Medicine, University of Vermont College of Medicine. The trial is designed as a multi-center, prospective, randomized controlled trial to evaluate the effect of RenalGuard(TM) in the prevention of Contrast-Induced Nephropathy (CIN) during cardiovascular and peripheral imaging procedures performed in a catheterization lab. PLC intends to begin enrollment in the RenalGuard Pivotal Trial in early 2008, following receipt of the necessary approval from the U.S. Food & Drug Administration.

full article >> http://money.cnn.com/news/newsfeeds/articles/prnewswire/NEW03119122007-1.htm